Molecular genetics of congenital erythropoietic porphyria.
Congenital erythropoietic porphyria (CEP), an autosomal recessive inborn error of heme biosynthesis, results from the markedly deficient activity of the cytosolic enzyme, uroporphyrinogen III synthase (URO-synthase). The accumulation of the nonphysiological and pathogenic porphyrin isomers, uroporphyrin I and coproporphyrin I, leads to the clinical manifestations of CEP. Disease severity in unrelated patients is markedly heterogeneous, ranging from fetal demise or severe transfusion dependency throughout life to milder adult cases with only cutaneous photosensitivity. To date, 18 mutations causing CEP have been described in the URO-synthase gene, including single base substitutions, insertions and deletions, and splicing defects. Most mutations have been identified in one or a few unrelated families with the exception of C73R, L4F, and T228M which occurred in about 33%, 8%, and 7% of the mutant alleles studied, respectively. Prokaryotic expression of the mutant URO-synthase alleles identified those with significant residual activity, thereby permitting genotype/phenotype predictions for severe to milder phenotypes of this clinically heterogeneous disease. As successful bone marrow transplantation in severely affected patients has proven curative, current efforts are underway to develop hematopoietic stem cell gene therapy for CEP.
Desnick
R J
RJ
Department of Human Genetics, Mount Sinai School of Medicine, New York, New York 10029, USA.
Glass
I A
IA
Xu
W
W
Solis
C
C
Astrin
K H
KH
D006801:Humans; D009154:Mutation; D017092:Porphyria, Erythropoietic / Q000175:diagnosis / Q000235:genetics* / Q000378:metabolism / Q000628:therapy; D014576:Uroporphyrinogen III Synthetase / Q000235:genetics
D014576:Uroporphyrinogen III Synthetase